Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

January 28th 2021

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

January 28th 2021

BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm

January 27th 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

Role of Therapeutic Intervention in SMM

January 27th 2021

Overview of Smoldering Multiple Myeloma

January 27th 2021

Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally

January 26th 2021

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL

January 26th 2021

January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

January 26th 2021

Rapid Readouts: Phase 2 JULIET Trial

January 26th 2021

Acalabrutinib Approved in Japan for Relapsed/Refractory CLL

January 25th 2021

January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

January 25th 2021

MRD Monitoring in FLT3 ITD AML

January 25th 2021

Assessing MRD Status in AML

January 25th 2021

Management of Ocular Events From DREAMM-2 Regimen

January 25th 2021

Oncology Community Mourns Joseph V. Simone, MD

January 23rd 2021

Joseph V. Simone, MD, a pioneering clinical investigator and institutional leader in pediatric oncology who was recognized with a 2017 Giants of Cancer Care® award, died January 21 at the age of 85.

Determining How to Incorporate MRD Into Care Decisions for Myeloma

January 22nd 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

Axicabtagene Ciloleucel Approved in Japan for Relapsed/Refractory LBCL

January 22nd 2021

January 22, 2021 — The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel for use in the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

January 22nd 2021